By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ZIOPHARM Oncology, Inc. 

1180 Avenue of the Americas
19th Floor
New York  New York  10036  U.S.A.
Phone: 646-214-0700 Fax: 646-214-0711


SEARCH JOBS








Company News
ZIOPHARM Oncology (ZIOP) Reports Second Quarter 2017 Financial Results And Provides Update On Recent Activities 8/1/2017 1:02:30 PM
ZIOPHARM Oncology (ZIOP) To Host Second-Quarter 2017 Financial Results And Corporate Update Conference Call On July 31, 2017 At 4:30 P.M. ET 7/24/2017 11:04:21 AM
ZIOPHARM Oncology (ZIOP) Announces Initiation Of Stereotactic Treatment Cohort In Phase I Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma 6/28/2017 9:58:48 AM
ZIOPHARM Oncology (ZIOP) Announces Positive Updated Results Of Ad-RTS-Hil-12 + Veledimex In Recurrent Glioblastoma At The 2017 ASCO Annual Meeting 6/5/2017 12:58:24 PM
ZIOPHARM Oncology (ZIOP) Announces Results Of Ad-RTS-hIL-12 + Veledimex In Recurrent Glioblastoma To Be Presented At The 2017 ASCO Annual Meeting 5/18/2017 11:21:31 AM
ZIOPHARM Oncology (ZIOP) Announces Pricing Of $50 Million Follow-On Offering Of Common Stock 5/12/2017 8:21:21 AM
ZIOPHARM Oncology (ZIOP) Announces FDA Acceptance Of IND For CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia 5/2/2017 8:29:05 AM
ZIOPHARM Oncology (ZIOP) Reports First Quarter 2017 Financial Results And Provides Update On Recent Activities 5/2/2017 8:27:20 AM
ZIOPHARM Oncology (ZIOP) To Host First-Quarter 2017 Financial Results And Corporate Update Conference Call On May 1, 2017 At 4:30 P.M. ET 4/24/2017 11:33:55 AM
ZIOPHARM Oncology (ZIOP) Release: Biopharma And Intrexon (XON) Announce Cooperative Research And Development Agreement With The NCI Utilizing Sleeping Beauty System To Generate T Cells Targeting Neoantigens 1/10/2017 10:42:37 AM
12345678910...
//-->